ENLICITIDE DECANOATE [USAN]

Merck's enlicitide decanoate (MK-0616, 20 mg once-daily oral) is the first oral pill in a PCSK9 inhibitor class currently dominated by injectable antibodies (Repatha, Praluent) and a twice-yearly siRNA (Leqvio). Three Phase 3 CORALreef LDL-C readouts published in 2026 in NEJM, JAMA, and JACC showed large LDL reductions: −55.8% versus placebo at 24 weeks in CORALreef Lipids [2] and −59.4% versus placebo in CORALreef HeFH [3], plus superiority over ezetimibe and bempedoic acid in the JACC head-to-head [1]. Merck has publicly indicated it intends to file an FDA NDA for a lipid-lowering indication based on this dataset [5][9]. The Phase 3 CORALreef Outcomes trial (NCT06008756, primary completion estimated November 29, 2029) is the swing vote: if it hits on major adverse cardiovascular events (MACE), Merck lands a differentiated oral cardiovascular asset off a $65B revenue base [4][5].

Novel first-in-class oral macrocyclic peptide PCSK9 inhibitor. No prior approval anywhere. The program is unusually mature for a node still labeled Phase 3: CORALreef Lipids (statin background, placebo-controlled), CORALreef HeFH (heterozygous familial hypercholesterolemia), and the head-to-head against oral nonstatin therapies (ezetimibe, bempedoic acid) have all reported positive Phase 3 lipid-lowering data in 2026 in top-tier journals, with LDL reductions of roughly 55 to 60% versus placebo [1][2][3]. NCT07216482 is a Phase 3 combination with rosuvastatin, now active-not-recruiting with n=975. Merck has publicly signaled an NDA filing based on the CORALreef LDL-C program is planned for 2026 [9], though as of the enrichment cutoff no FDA breakthrough, fast track, or priority review designations have been disclosed for enlicitide. The larger CORALreef Outcomes cardiovascular endpoint trial (NCT06008756, primary completion November 29, 2029) will read out later and drives the commercial ceiling. Merck is also pairing enlicitide with MK-7262, an investigational Lp(a)-lowering agent, in Phase 1 and Phase 2 studies (NCT07619443, NCT07614984), signaling a broader lipid franchise build rather than a one-indication play.

PCSK9 is a protein made by the liver that acts as a wrecking crew for LDL receptors. LDL receptors sit on liver cell surfaces and pull LDL cholesterol out of the blood. PCSK9 grabs those receptors and drags them inside the cell where they get destroyed instead of recycled. Fewer receptors means less LDL cleared, higher blood cholesterol. Block PCSK9, and the receptors stay on the surface longer, pulling more LDL out of circulation. The target is one of the most genetically bulletproof in cardiovascular medicine: people born with loss-of-function PCSK9 mutations have low LDL and low heart attack rates, while gain-of-function carriers get severe familial hypercholesterolemia. Injectable monoclonal antibodies against PCSK9 (evolocumab in FOURIER, alirocumab in ODYSSEY OUTCOMES) both cut MACE in outcomes trials, so the mechanism-to-outcome bridge is built. Enlicitide's twist is chemistry, not target biology: it is a macrocyclic peptide small and stable enough to survive the gut and reach the PCSK9-LDL receptor interface after 20 mg once-daily oral dosing. Prior attempts at oral PCSK9 blockade failed on bioavailability. Merck's placebo-controlled NEJM Phase 3 confirms enlicitide clears that bar in humans with a 55.8% LDL-C reduction versus placebo at 24 weeks [2].

CORALreef Outcomes (NCT06008756) is the cardiovascular endpoint trial, testing whether enlicitide reduces MACE (CHD death, ischemic stroke, MI, acute limb ischemia or major amputation, or urgent arterial revascularization) in high-risk hypercholesterolemic patients on background statin therapy versus placebo. Primary completion is estimated November 29, 2029 [5]. Outcomes trials of this design are the standard bar for PCSK9 approval expansion beyond LDL-lowering, following the FOURIER and ODYSSEY OUTCOMES templates. The already-reported CORALreef LDL-C program is stronger evidence than most Phase 3 assets ever accumulate before their key readout: the placebo-controlled NEJM study established a −55.8% adjusted between-group LDL-C difference at 24 weeks [2], the JAMA HeFH trial demonstrated a −59.4% reduction in the highest-genetic-risk population where PCSK9 mAbs made their initial commercial case [3], and the JACC head-to-head versus oral nonstatin therapies (ezetimibe, bempedoic acid) directly attacks the incumbent oral second-line lipid market [1]. The pediatric HeFH Phase 2 (NCT07058077, n=153) opens a label extension pathway once adult approval lands. The main design question the outcomes trial will answer is whether the ~55 to 60% LDL reduction translates proportionally to MACE reduction, which the Cholesterol Treatment Trialists' meta-analyses and PCSK9 mAb outcomes data both predict it should.

Our model estimates a 44% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and more secondary endpoints than usual; it is held back by weak or limited earlier-phase results and heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy: oral macrocyclic peptides typically achieve lower absolute exposure than injected monoclonal antibodies, and while the CORALreef LDL data confirm the pharmacology works (55 to 60% LDL reduction across the program [1][2][3]), the outcomes trial has to demonstrate that reduction translates proportionally to MACE. The Cholesterol Treatment Trialists' relationship predicts it should, but the field has been humbled before (CETP inhibitors torcetrapib and evacetrapib both cleared lipid endpoints and failed on outcomes). Safety: long-term chronic dosing of a novel peptide in a hypertensive, diabetic, elderly population will surface anything the shorter Phase 3 studies missed. PCSK9 mAbs have a clean long-term safety record, which is encouraging but not dispositive for a different molecular class. Execution: outcomes trials of this size run to 2029 and cost hundreds of millions; Merck can absorb this, but delays or event-rate shortfalls have derailed similar programs. Commercial: this is the sharpest risk. Generic statins cost $4 a month. Ezetimibe is generic. Bempedoic acid is available. Evolocumab and alirocumab prices have been slashed to roughly $500 a month and biosimilars are approaching. Inclisiran needs only two injections a year. An oral daily pill from Merck will land into a crowded, price-compressed market where payers already restrict PCSK9 access to high-risk patients failing statins plus ezetimibe. Analyst peak sales estimates for enlicitide have clustered in the $3 to 5B range on an outcomes-driven label, but that upside is contingent on the MACE readout and payer coverage decisions.

Watch closely. This is Merck's most credible near-term cardiovascular asset and the first genuine test of whether oral PCSK9 inhibition can compete commercially against injectable and siRNA incumbents. The near-term catalyst: FDA acceptance of Merck's NDA for a lipid-lowering indication based on the CORALreef LDL-C program (NEJM, JAMA, JACC 2026 [1][2][3]), which Merck has publicly indicated it plans to file [9]. If Merck secures a lipid-lowering label in 2026 or 2027, they can build commercial and safety experience while the outcomes trial matures to its estimated November 29, 2029 primary completion [5]. The bigger binary is the CORALreef Outcomes MACE readout itself, which will determine whether enlicitide is a niche second-line lipid agent or a franchise product. Merck's 2025 10-K identifies cardiovascular as a strategic growth area after Keytruda (pembrolizumab) loses patent exclusivity around 2028, which will remove Merck's largest revenue source ($25B+ annually) [4]. The MK-7262 combination trials in Lp(a) (NCT07614984) reinforce that lipid franchise strategy: Lp(a) is a genetically-driven cardiovascular risk factor that statins and PCSK9 inhibitors do not meaningfully lower, so a Lp(a)-directed pairing addresses a residual-risk population that enlicitide monotherapy cannot reach [7]. Check back on: FDA acceptance and action dates on the LDL-C NDA, competitive commentary from Amgen (Repatha), Regeneron/Sanofi (Praluent), and Novartis (Leqvio) about oral PCSK9 threat on their quarterly calls, and the CORALreef Outcomes interim analysis timing when Merck discloses it on earnings.